Recruiting
Phase 2

Romosozumab/Denosumab Study for Premenopausal IOP

Sponsor:

Columbia University

Code:

NCT04800367

Conditions

Premenopausal Idiopathic Osteoporosis

Eligibility Criteria

Sex: Female

Age: 18 - 45

Healthy Volunteers: Not accepted

Interventions

Romosozumab Prefilled Syringe [Evenity]

Denosumab 60 MG/ML Prefilled Syringe [Prolia]

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information